Clinical Trial Title Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Trial Status Open to Enrollment
Start Date 10/05/2011
Location randall-childrens-hospital-at-legacy-emanuel
Trial Type Pediatric Cancer (Oncology)
Specific Condition Acute Lymphoblastic Leukemia (ALL) High Risk B-precursor
Description This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.
Eligibility Criteria Patients must be enrolled on the COG AALL08B1 Classification Study prior to enrollment on AALL1131.

Age:   >365 days and <31 Years of Age

White Blood Cell Count (WBC) Criteria:

  • Age 1-9.99 years: WBC >50,000/uL
  • Age 10-30.99 years: Any WBC
  • Age 1-30.99 years: Any WBC with: a) testicular leukemia, b) CNS leukemia (CNS3), c) steroid pretreatment
High risk or standard risk ALL with central nervous system (CNS), testicular leukemia, and/or steroid pre-treatment

Standard Risk ALL patients enrolled on the COG AALL0932 (Standard Risk Study) and completed Induction treatment and been classified as High Risk or Very High Risk Newly diagnosed B-precursor ALL

Patients with Down Syndrome are also eligible

Patients must not have received any prior cytotoxic chemotherapy for the current diagnosis of ALL or any cancer diagnosed previously, with the exception of steroids and intrathecal cytarabine for the current diagnosis of ALL

Patients cannot have secondary ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy
IRB Number
Principal Investigator Janice Olson, MD
Contact Name Children's Cancer and Blood Disorders Program
Contact Phone (503) 276-9300
Contact Fax
Contact E-Mail